Date: 2014-06-12
Type of information: Initiation of the trial
phase: 2
Announcement: initiation of the trial
Company: Eli Lilly (USA - IN)
Product: galunisertib (LY2157299)
Action mechanism:
Disease: hepatocellular carcinoma
Therapeutic area: Cancer - Oncology
Country: China, Hong Kong, Republic of Korea, Taiwan, Thailand
Trial
details: The main purpose of this study is to evaluate the safety and effectiveness of galunisertib (LY2157299) in participants with hepatocellular carcinoma.
Latest
news: * On June 12, 2014, a Phase 2 trial sponsored by Eli Lilly was published on the NIH website ClinicalTrials.gov galunisertib and is currently ongoing.
